The Data and Safety Monitoring Plan, adopted by the H. Lee Moffitt Cancer Center and Research Institute originally in 2002 and revised repeatedly throughout the grant period, ensures that all clinical research conducted or coordinated by the Cancer Center is scientifically well designed, responsibly managed, appropriately reported, and that it protects the rights and welfare of human participants. The institutional plan conforms to NIH and NCI policies and guidelines regarding data and safety monitoring. The methodology and amount of monitoring required are dictated by the degree of risk involved to the individual patients and the complexity of the clinical research. Because the specific types of monitoring and reporting needed vary by the nature of the individual trial, the responsibility for ensuring that monitoring is appropriate, timely, and effective encompasses a number of Cancer Center individuals and groups. The Associate Center Director for Clinical Investigations has overall responsibility for data and safety monitoring, and the Protocol Monitoring Committee (PMC) is the Institution's venue for review of all monitoring reports. The PMC has a separate and distinct function from the Scientific Review Committee and the IRB. Its primary tasks are to: ? Assess safety by reviewing severe adverse event reports from investigator-initiated studies and monitor their timely and appropriate reports to oversight agencies (such as the IRB, FDA, or NCI). ? Review audits of investigator-initiated clinical trials ? Review interim data and safety reports from investigator-initiated studies ? Review the interim and final reports from the external Data Safety and Monitoring Board The Protocol Monitoring Committee (PMC), chaired by Scott Antonia, MD, PhD, includes members from a variety of the Cancer Center's clinical and scientific programs who have extensive experience with clinical research. The DSM requests CCSG Support of $72,617 for support of Protocol Monitoring Committee activities.

Public Health Relevance

Data and Safety Monitoring at Moffitt provides a level of monitoring during clinical trials that is necessary to protect the safety of human subjects and to ensure the validity and scientific integrity of clinical trial data.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-15
Application #
8495983
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
15
Fiscal Year
2013
Total Cost
$40,622
Indirect Cost
$16,513
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Schaal, Courtney M; Bora-Singhal, Namrata; Kumar, Durairaj Mohan et al. (2018) Regulation of Sox2 and stemness by nicotine and electronic-cigarettes in non-small cell lung cancer. Mol Cancer 17:149
Zhu, Genyuan; Brayer, Jason; Padron, Eric et al. (2018) OMIP-049: Analysis of Human Myelopoiesis and Myeloid Neoplasms. Cytometry A 93:982-986
Bowman-Curci, Meghan; Quinn, Gwendolyn P; Reinecke, Joyce et al. (2018) Comparing fertility preservation resources and policies between NCCN member and non-member institutions. Support Care Cancer :
Hampras, Shalaka S; Locke, Frederick L; Chavez, Julio C et al. (2018) Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients. Leuk Lymphoma 59:911-917
Kim, Youngchul; Pierce, Christine M; Robinson, Lary A (2018) Impact of viral presence in tumor on gene expression in non-small cell lung cancer. BMC Cancer 18:843
Persi, Erez; Duran-Frigola, Miquel; Damaghi, Mehdi et al. (2018) Systems analysis of intracellular pH vulnerabilities for cancer therapy. Nat Commun 9:2997
Rosenberger, Albert; Hung, Rayjean J; Christiani, David C et al. (2018) Genetic modifiers of radon-induced lung cancer risk: a genome-wide interaction study in former uranium miners. Int Arch Occup Environ Health 91:937-950
Chen, Yan; Zhu, Jin-Yi; Hong, Kwon Ho et al. (2018) Structural Basis of ALDH1A2 Inhibition by Irreversible and Reversible Small Molecule Inhibitors. ACS Chem Biol 13:582-590
Kahen, Elliot John; Brohl, Andrew; Yu, Diana et al. (2018) Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors. Oncotarget 9:22571-22585
Hoffman, Melissa A; Fang, Bin; Haura, Eric B et al. (2018) Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer. J Proteome Res 17:63-75

Showing the most recent 10 out of 1254 publications